Order Paper

Data sources & licences Contact us

Contains Parliamentary information licensed under the Open Parliament Licence v3.0. Contains public sector information licensed under the Open Government Licence v3.0. © Parliamentary copyright. © Crown copyright.

Today Browse Your MP Calendar

Parliamentary Written Questions 53263 and… · Order Paper · Order Paper

HANSARDCommons28 Apr 20221 contribution

Parliamentary Written Questions 53263 and 53380: Correction

View on hansard.parliament.uk ↗

The Parliamentary Under-Secretary of State for Health and Social Care (Maria Caulfield)
ConservativeLewes
I would like to inform the House that written answers I gave on 18 and 21 October 2021 Official Report 53263 and 53380 to the hon. Member for Bootle (Peter Dowd) were incorrect.
In the response to the written questions, I said that radioligand therapy is not yet licensed for the National Health Service (NHS) and has yet to receive approval from the National Institute for Health and Care Excellence (NICE). That was incorrect. A licensed radioligand treatment, Lutetium (177Lu) oxodotreotide, has been recommended by NICE for treating unresectable or metastatic neuroendocrine tumours (NICE Technology appraisal guidance [TA539] Published: 29 August 2018). The NHS funds Lutetium in line with NICE’S recommendations and is treating the expected number of patients estimated by NICE:
https://www.nice.org.uk/Guidance/ta539/chapter/1-Recommendations
NICE is also now developing guidance on Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after two or more therapies and currently expects to publish final guidance on 23 November 2022. This technology was granted a positive early access to medicine scientific opinion in April 2022 and is currently available to NHS patients as an unlicensed treatment.
[HCWS800]